Natco Pharma unveils drug to treat epilepsy

Published - February 26, 2021 11:27 pm IST - HYDERABAD

Natco Pharma has unveiled Brivaracetam tablets, indicated for treatment of epilepsy, under the Brecita brand in the country.

Brivaracetam is developed by UCB Pharma and currently being marketed by Dr. Reddy’s Laboratories in India under the brand name Briviact. Natco Pharma’s Brecita tablets will be available in two strengths of 50mg and 100mg at “significantly lower MRP of ₹25 and ₹35 per tablet respectively,” the company said on Friday. It also citied GEMIND guidelines that estimated number of epilepsy patients in the country to be in the range of 5-10 million.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.